Developmental biology

Laekna Therapeutics Appoints Jeff Porter, Ph.D. as Chairman of Scientific Advisory Board

Retrieved on: 
Tuesday, March 29, 2022
Therapy, Novartis Institute for Tropical Diseases, Leadership, Developmental biology, Multimedia, Johns Hopkins, RNA splicing, United States Air Force Scientific Advisory Board, Cancer, RNA, Howard Hughes Medical Institute, Molecular biology, View, Johns Hopkins School of Medicine, Technology, NIBR, Doctor of Philosophy, Drug discovery, SAB, Chemical biology, Department, Genetics, Cirrhosis, Biomedical Research, Medical device, Pharmaceutical industry, Biochemistry, Research, Novartis

SHANGHAI and WARREN, N.J., March 29, 2022 /PRNewswire/ -- Laekna Therapeutics, a clinical-stage global biotechnology companyannounced today the appointment of Jeff Porter, Ph.D. as the Chairman of its Scientific Advisory Board (SAB).

Key Points: 
  • SHANGHAI and WARREN, N.J., March 29, 2022 /PRNewswire/ -- Laekna Therapeutics, a clinical-stage global biotechnology companyannounced today the appointment of Jeff Porter, Ph.D. as the Chairman of its Scientific Advisory Board (SAB).
  • He will work with several other senior industrial and academic leaders to provide scientific governance and guide Laekna Therapeutics in developing the next generation of medicines to treat cancer and liver fibrosis.
  • "We are honored to have Dr. Porter join us and lead our Scientific Advisory Board.
  • "Laekna Therapeutics has an exciting and globally competitive pipeline of potential new therapies and early projects, " said Dr. Porter.

Element Biosciences Partners with Dovetail Genomics to Validate its Proximity Ligation-Based NGS Library Prep Solutions for Epigenetics on Element’s AVITI™ System

Retrieved on: 
Thursday, February 24, 2022
Science, Biotechnology, Research, Pharmaceutical, Health, Medical Devices, Genetics, Other Health, Partnership, Genomics, Element, Genome, PT, Architecture, Senior, Bureau of Oceans and International Environmental and Scientific Affairs, Chromatin, NGS, Technology, Developmental biology, Research, CET, Antibiotics, Dovetail joint

Element Biosciences, Inc., developer of a new and disruptive DNA sequencing platform, today announced a partnership with Dovetail Genomics demonstrating the value and performance of Dovetails proximity ligation-based next-generation sequencing (NGS) library prep solutions on Elements AVITI System.

Key Points: 
  • Element Biosciences, Inc., developer of a new and disruptive DNA sequencing platform, today announced a partnership with Dovetail Genomics demonstrating the value and performance of Dovetails proximity ligation-based next-generation sequencing (NGS) library prep solutions on Elements AVITI System.
  • Dovetail Genomics best-in-class products and services capture 3D genome architecture alongside primary sequence information using NGS approaches.
  • We are pleased to form a partnership with Dovetail Genomics to deliver seamless compatibility between the AVITI System and Dovetails library preparation kits.
  • We are thrilled to partner with Element Biosciences to add Dovetail Genomics cutting-edge proximity ligation technology to this new and exciting NGS platform, said Dovetail CEO Todd Dickinson.

Trestle Biotherapeutics Announces Formation of Advisory Board

Retrieved on: 
Wednesday, February 23, 2022
Biotechnology, Hospitals, Genetics, Health, Entrepreneurship, Massachusetts General Hospital, Harvard Medical School, Faculty, Wyss Institute, Eli, Bionics, Kidney, Department, Hospital, University, Tissue engineering, Laboratory, Wyss Institute for Biologically Inspired Engineering, Transplant, Stem cell, Engineering, Nephrology, Regenerative medicine, Coronavirus Scientific Advisory Board (Turkey), Patient, Harvard University, Drug discovery, Wyss, AV, HAV, Developmental biology, Bioinspiration, Kidney failure, Protalix BioTherapeutics, CEO, Pharmaceutical industry, Management, Brigham, Trestle bridge

Trestle Biotherapeutics, a private, San Diego-based company developing bioengineered therapies for patients living with kidney failure today announced the formation of its advisory board.

Key Points: 
  • Trestle Biotherapeutics, a private, San Diego-based company developing bioengineered therapies for patients living with kidney failure today announced the formation of its advisory board.
  • The Trestle Advisory Board is a balanced mix of academic and industry leaders who are world renowned scientific experts in the fields of 3D biofabrication, stem cell and developmental biology, tissue engineering, immunology, and nephrology.
  • The composition of our advisory board reflects that approach, and we are proud to have them join us and help guide the effort, said Ben Shepherd, Co-Founder and CEO of Trestle.
  • In addition, Laura Niklason, M.D., Ph.D., Co-Founder and CEO of Humacyte has agreed to join the Trestle advisory board.

City of Hope awarded $4.9 million from CIRM to train future leaders in stem cell biology and regenerative medicine

Retrieved on: 
Tuesday, February 22, 2022
Research, General Health, Philanthropy, Training, University, Education, Science, Other Philanthropy, Sailing, Other Science, Health, Diabetes, Division, City of Hope, Ethics, California Institute for Regenerative Medicine, National Cancer Institute, Digestive, Beckman Research Institute, Twitter, Morgan Chu, Diabetes, Kidney, Department, Biology, Education, Research, Regenerative medicine, Irell & Manella Graduate School of Biological Sciences, CAR, Laboratory, Medicine, Organization, Regeneration, National Institute of Diabetes and Digestive and Kidney Diseases, Cancer, Cancer Treatment Centers of America, Lists of diseases, Haematopoietic system, Biomedical Research, LinkedIn, DNA, Degenerative disease, Translational Genomics Research Institute, DNA repair, CIRM, Instagram, YouTube, Patient, Student, Technology, Walking, Immunotherapy, Developmental biology, Program, National Institute, Health, Pharmaceutical industry, Hospital, Faculty, Facebook, City, Hope, Neuroscience

City of Hope has an integrated, multidisciplinary approach to translating fundamental research findings into clinical practice for patients benefit.

Key Points: 
  • City of Hope has an integrated, multidisciplinary approach to translating fundamental research findings into clinical practice for patients benefit.
  • Instruction will come from scientific and clinical faculty, research nurses and experts in the ethics of stem cell research and its application to medicine.
  • This program originates from City of Hopes longstanding expertise in conducting clinical trials and applying fundamental stem cell biology and gene therapy to the treatment of diseases.
  • For more information about City of Hope, follow us on Facebook , Twitter , YouTube , Instagram and LinkedIn .

Trestle Biotherapeutics Announces License Agreement with Kumamoto University for Key Stem Cell Biology Technology for Regenerative Medicine

Retrieved on: 
Tuesday, February 15, 2022
Research, Genetics, Stem Cells, Biotechnology, Health, University, General Health, Science, Education, Potency (pharmacology), Patient, CEO, Developmental biology, School, Kidney, Kidney failure, Entrepreneurship, Protalix BioTherapeutics, CSO, Education, Dialysis, Therapy, Technology, Institute, Survival, Transplant, Partnership, Kumamoto University, Research, Embryology, Industry, Pharmaceutical industry, Trestle bridge, Genetics, Trestle Biotherapeutics, Kumamoto University, TRESTLE BIOTHERAPEUTICS, KUMAMOTO UNIVERSITY

Trestle Biotherapeutics , a private company based in San Diego, today announced that it has entered into a license agreement with Kumamoto University.

Key Points: 
  • Trestle Biotherapeutics , a private company based in San Diego, today announced that it has entered into a license agreement with Kumamoto University.
  • Under the agreement, Trestle will gain access to foundational methods for the generation of specialized kidney cell types from human pluripotent stem cells.
  • Dr. Nishinakamura is a world-renowned kidney developmental biologist and a pioneer in the fields of kidney stem cell differentiation and organoid biology.
  • Trestle is building these novel tissue therapeutics through the integration of stem cell biology and 3D biofabrication technologies.

FUJIFILM VisualSonics and PIUR IMAGING Partner to Enable Ultra-High Frequency, 3D Ultrasound Imaging Technology

Retrieved on: 
Thursday, February 10, 2022
CT, Gesellschaft mit beschränkter Haftung, GLOBE, FUJIFILM, Neuroscience, Algorithm, Acquisition, Solution, Software, Neurology, Sale, Dermatology, Technology, Anatomy, Patient, Knowledge, CTO, Infinity, Anomaly, Workflow, Vivo, 3D, FUJIFILM VisualSonics, UHF, Fujifilm, Developmental biology, Partnership, Vevo, MSK, MD, Medical imaging

Toronto & Vienna, Feb. 10, 2022 (GLOBE NEWSWIRE) -- February 10, 2022 - FUJIFILM VisualSonics , a global provider of ultra-high-frequency (UHF) ultrasound imaging systems, and PIUR IMAGING , the European leader in tomographic ultrasound imaging, have partnered to bring UHF, three-dimensional (3D) ultrasound imaging technology to clinicians and researchers.

Key Points: 
  • Toronto & Vienna, Feb. 10, 2022 (GLOBE NEWSWIRE) -- February 10, 2022 - FUJIFILM VisualSonics , a global provider of ultra-high-frequency (UHF) ultrasound imaging systems, and PIUR IMAGING , the European leader in tomographic ultrasound imaging, have partnered to bring UHF, three-dimensional (3D) ultrasound imaging technology to clinicians and researchers.
  • The FUJIFILM VisualSonics Vevo MD , coupled with PIUR IMAGINGs tUS Infinity platform, offers researchers and clinicians the ability to visualize and measure ultrasound volumes in 3D, said Greg Nesbitt, vice president, global high frequency, FUJIFILM VisualSonics.
  • When combined with FUJIFILM VisualSonics Vevo MD ultrasound imaging system, this produces three-dimensional UHF ultrasound volumetrics.
  • The combination of FUJIFILM VisualSonics and PIUR IMAGING technologies creates the industrys first handheld, UHF, 3D ultrasound imaging technology.

Trestle Biotherapeutics Licenses Innovations from Harvard University to Develop 3D Biofabricated Tissues to Treat Kidney Failure

Retrieved on: 
Tuesday, February 8, 2022
Research, General Health, University, Genetics, Education, Public Relations, Investor Relations, Clinical Trials, Science, Biotechnology, Communications, Other Science, Health, Kidney, Bioinspiration, Harvard John A. Paulson School of Engineering and Applied Sciences, Developmental biology, Harvard Medical School, Solution, Protalix BioTherapeutics, Wyss, Technology, Patient, Faculty, Applied science, Survival, Tissue, Bionics, CEO, SEAS, Hospital, Wyss Institute for Biologically Inspired Engineering, Therapy, Entrepreneurship, Kidney failure, Dialysis, Regenerative medicine, Harvard University, Laboratory, Massachusetts General Hospital, Nature, Transplant, Wyss Institute, Pharmaceutical industry, Dentistry, Engineering, Trestle bridge, Brigham, Yoshiko Morizane, DRS

Trestle Biotherapeutics , a private company based in San Diego, today announced that it has entered into a license agreement with Harvard University.

Key Points: 
  • Trestle Biotherapeutics , a private company based in San Diego, today announced that it has entered into a license agreement with Harvard University.
  • Trestle is developing functional kidney tissue to supplement and replace lost renal function in kidney failure patients.
  • Trestle is building these novel tissue therapeutics through the integration of stem cell biology and 3D biofabrication technologies.
  • Trestle was founded with the belief that recreating patterns and processes found in nature is key to building functional tissues.

Stemson Therapeutics Announces Additions To Its Scientific Advisory Board

Retrieved on: 
Tuesday, February 1, 2022
Health, Stem Cells, Other Health, Clinical Trials, Pharmaceutical, Biotechnology, Growth, Eye, Patient, Therapy, Pathology, Cell, National Eye Institute, Program, National, Skin, Regeneration, Developmental biology, Technology, IPSC, Doctor of Philosophy, United States Air Force Scientific Advisory Board, Hair follicle, William Stemson, Hair, Potency (pharmacology), NIH, SAB, Retinal pigment epithelium, Wound healing, Harvard University, AMD, Harvard Medical School, Regenerative medicine, Solution, HSCI, CA, B cell, Medical device, Pharmaceutical industry, Brigham, Dermatopathology, Hair loss

to its Scientific Advisory Board (SAB).

Key Points: 
  • to its Scientific Advisory Board (SAB).
  • We are delighted and honored to welcome Dr. Bharti and Dr. Murphy to our SAB to enhance our world-class group of scientific advisors supporting the company, said Stemson Therapeutics cofounder and Chief Executive Officer, Geoff Hamilton.
  • I am excited to join the SAB at Stemson Therapeutics and support their work to develop an autologous iPSC cell therapy to treat hair loss, stated Dr. Bharti.
  • Stemson Therapeutics is headquartered in San Diego, CA.

First Platform for Massively Multiplexed Single-Cell In Situ Spatial Genomics Now Broadly Available to U.S. Market

Retrieved on: 
Tuesday, January 18, 2022
Science, Other Science, Research, Research, Technology, Actinin alpha 3, LinkedIn, Liver, Biology, Translational Genomics Research Institute, Genomics, Emerging technologies, Nutrient, Old, Science, Gene, CEO, Social media, Allen Institute for Brain Science, Hepatocyte, Â, Oxygen, Disease, Center, Health, Regenerative medicine, Map, DAPI, Tissue, Infection, Efficiency, Associate, CYP1A2, Allen Institute, Multimedia, Neuroscience, Developmental biology, Twitter, Cell, Brain, Allen, Drug discovery, Data visualization, Medical imaging, Microscope, Facebook, the Data Release Program at Vizgen, the Interactive Web Visualizer, Vizgen, THE DATA RELEASE PROGRAM AT VIZGEN, THE INTERACTIVE WEB VISUALIZER, VIZGEN

(Photo: Business Wire)

Key Points: 
  • (Photo: Business Wire)
    Through MERSCOPE, a one-of-a-kind single-cell spatial genomics platform technology, Vizgen is ushering in a new era in genomics.
  • We are working with our customers to bring new platform capabilities and applications throughout the year and continue to lead this new era of spatial genomics.
  • Vizgen is dedicated to pioneering the next generation of genomics, providing tools that demonstrate the possibilities of in situ single-cell spatial genomics, setting the standard for the spatial genomics field.
  • The company's MERSCOPETM Platform enables massively multiplexed, genome-scale nucleic acid imaging with high accuracy and unrivaled detection efficiency at subcellular resolution.

Singular Genomics Partners with Dovetail Genomics to Enable Dovetail Kits for the G4 Sequencing Platform

Retrieved on: 
Monday, January 10, 2022
Singular, SEC, OMIC, Dovetail joint, Genome, Gene expression, Chromatin, G4, Federal, Precision medicine, Science, Partnership, Genomics, Proteomics, Solution, PX, Senior, NGS, Spatial analysis, Risk, Corporate development, Nasdaq, Medicine, Developmental biology, GLOBE, Antibiotics

The long-range genomic information captured by Dovetail technology will enable more comprehensive detection of structural variation and chromosome-scale phasing on the Singular Genomics platform.

Key Points: 
  • The long-range genomic information captured by Dovetail technology will enable more comprehensive detection of structural variation and chromosome-scale phasing on the Singular Genomics platform.
  • We are pleased to announce our partnership with Dovetail to make their kits available to Singular Genomics customers.
  • With Dovetails unbiased proximity ligation technology, Singular Genomics users will be able to create a richer view of the genome from every sequencing run, said Dovetail CEO Todd Dickinson.
  • We are thrilled to be partnering with Singular Genomics to enable researchers to accelerate critical advancements in precision medicine and life sciences research.